Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Peking University

Status: Completed

Conditions: Soft Tissue Sarcoma; Refractory Tumor; Bone Sarcoma

Treatments: Drug: Fruquintinib

Study type: Observational

Funder types: Other

Identifiers

NCT06202599

PKUPH-sarcoma 17

Details and patient eligibility

About

This multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of TKIs' resistance.

Full description

The short-lived duration of disease control and secondary drug resistance have posed a threat to the effect of TKIs. Fruquintinib is a novel TKI with a high selectivity of VEGFR-1,2,3 without metabolism by liver enzymes and was approved for application in mCRC. Serious drug resistance and the unique characteristics of fruquintinib have prompted us to verify whether this drug can reverse TKIs' resistance at a higher dose.

Enrollment: 124 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically confirmed bone or soft tissue sarcomas;
2. Progressed after several lines of therapy;
3. Previously treated with other TKIs before fruquintinib;
4. Received fruquintinib-based treatment;
5. Measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST) version1.1;
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤3

Exclusion criteria

1. Failure to complete regular follow-up after administration.
2. Discontinued the fruquintinib-based treatment due to neither progression nor unacceptable toxicity.

Trial design

124 participants in 1 patient group

Study group

Description:

Fruquintinib treatment group

Treatment:

Drug: Fruquintinib